Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. Among authors: paolini j. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Free article. Clinical Trial.
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.
Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, Camidge DR. Soria JC, et al. Among authors: paolini j. Ann Oncol. 2018 Sep 1;29(9):1964-1971. doi: 10.1093/annonc/mdy242. Ann Oncol. 2018. PMID: 30010763 Free article.
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Solomon BJ, et al. Among authors: paolini j. J Clin Oncol. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888. Epub 2016 Mar 28. J Clin Oncol. 2016. PMID: 27022118 Clinical Trial.
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS. Solomon BJ, et al. Among authors: paolini j. J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. Epub 2018 May 16. J Clin Oncol. 2018. PMID: 29768118 Clinical Trial.
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC.
Wu YL, Lu S, Yang JC, Zhou J, Seto T, Ahn MJ, Su WC, Yamamoto N, Kim DW, Paolini J, Usari T, Iadeluca L, Wilner KD, Goto K. Wu YL, et al. Among authors: paolini j. JTO Clin Res Rep. 2022 Sep 9;3(10):100406. doi: 10.1016/j.jtocrr.2022.100406. eCollection 2022 Oct. JTO Clin Res Rep. 2022. PMID: 36247019 Free PMC article.
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Gambacorti-Passerini C, et al. Among authors: paolini j. Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. Epub 2018 Feb 8. Am J Hematol. 2018. PMID: 29352732 Free PMC article. Clinical Trial.
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I. Michaelson MD, et al. Among authors: paolini j. J Clin Oncol. 2014 Jan 10;32(2):76-82. doi: 10.1200/JCO.2012.48.5268. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323035 Clinical Trial.
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH Jr, Tassell V, Huang X, Paolini J, Kern KA, Romieu G. Crown JP, et al. Among authors: paolini j. J Clin Oncol. 2013 Aug 10;31(23):2870-8. doi: 10.1200/JCO.2012.43.3391. Epub 2013 Jul 15. J Clin Oncol. 2013. PMID: 23857972 Clinical Trial.
170 results